Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
GASC
MCID: GST053
MIFTS: 83

Gastric Cancer (GASC)

Categories: Blood diseases, Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Gastric Cancer

About this section

MalaCards integrated aliases for Gastric Cancer:

Name: Gastric Cancer 57 12 20 73 36 54
Stomach Cancer 12 74 20 73 29 42 15
Stomach Carcinoma 12 20 15 71
Gastric Carcinoma 12 54 17
Malignant Neoplasm of Stomach 71 32
Stomach Neoplasms 44 71
Gastric Neoplasm 12 6
Malignant Tumor of Lesser Curve of Stomach 71
Malignant Neoplasm of Body of Stomach 71
Gastric Cancer Intestinal 73
Gastric Cancer, Somatic 57
Adult Stomach Carcinoma 20
Cancer of the Stomach 12
Carcinoma of Stomach 12
Adult Stomach Cancer 20
Gastric Carcinomas 15
Stomach Neoplasm 17
Gastric Cancers 15
Cancer, Gastric 39
Gasc 73

Characteristics:

HPO:

31
gastric cancer:
Inheritance somatic mutation


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Immune diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:10534 DOID:5517
OMIM® 57 613659
KEGG 36 H00018
MeSH 44 D013274
SNOMED-CT via HPO 68 124975008 372143007
UMLS 71 C0024623 C0038356 C0153421 more
Sources

Summaries for Gastric Cancer

About this section
GARD : 20 Stomach cancer, also called gastric cancer, is a form of cancer that occurs due to abnormal and uncontrolled cell growth in the stomach. Most people with early stomach cancer have no signs or symptoms of the condition. In advanced stages, symptoms may include indigestion; nausea and vomiting; difficulty swallowing; feeling full after eating small amounts of food; loss of appetite; vomiting blood; fatigue; and/or weight loss. Most cases of stomach cancer occur sporadically in people with little to no family history of the condition; however, approximately 10% of stomach cancers are considered "familial." Although the underlying cause of some familial cases is unknown, genetic changes (mutations) are identified in a subset of people affected by stomach cancer. Hereditary cancer syndromes associated with a predisposition to stomach cancer include hereditary diffuse gastric cancer, Lynch syndrome, Li-Fraumeni syndrome, familial adenomatous polyposis, and Peutz-Jeghers syndrome. In other families, a cluster of stomach cancers may be due to a combination of gene(s) and/or other shared factors such as environment and lifestyle. The best treatment options for stomach cancer depend on many factors including the stage of the condition and may include surgery, chemotherapy, radiation therapy, and/or targeted therapy (such as monoclonal antibody therapy).

MalaCards based summary : Gastric Cancer, also known as stomach cancer, is related to gastric adenocarcinoma and esophageal cancer, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Gastric Cancer is APC (APC Regulator Of WNT Signaling Pathway), and among its related pathways/superpathways are Gastric cancer and PI3K-Akt signaling pathway. The drugs Clopidogrel and Pravastatin have been mentioned in the context of this disorder. Affiliated tissues include stomach, lymph node and liver, and related phenotypes are stomach cancer and increased level of l-fucose in urine

Disease Ontology : 12 A gastrointestinal system cancer that is located in the stomach.

OMIM® : 57 In a review article on the genetic predisposition to gastric cancer, Bevan and Houlston (1999) concluded that several genes may be associated with an increased risk of gastric cancer. Gastric cancer is a manifestation of a number of inherited cancer predisposition syndromes, including hereditary nonpolyposis colon cancer (HNPCC1; see 120435), familial adenomatous polyposis (FAP; 175100), Peutz-Jeghers syndrome (PJS; 175200), Cowden disease (CD; 158350), and the Li-Fraumeni syndrome (151623). See also hereditary diffuse gastric cancer (HDGC; 137215). Canedo et al. (2007) provided a review of genetic susceptibility to gastric cancer in patients infected with Helicobacter pylori (see 600263). (613659) (Updated 05-Mar-2021)

MedlinePlus : 42 The stomach is an organ between the esophagus and the small intestine. It mixes food with stomach acid and helps digest protein. Stomach cancer mostly affects older people - two-thirds of people who have it are over age 65. Your risk of getting it is also higher if you Have had a Helicobacter pylori infection Have had stomach inflammation Are a man Eat lots of salted, smoked, or pickled foods Smoke cigarettes Have a family history of stomach cancer It is hard to diagnose stomach cancer in its early stages. Indigestion and stomach discomfort can be symptoms of early cancer, but other problems can cause the same symptoms. In advanced cases, there may be blood in your stool, vomiting, unexplained weight loss, jaundice, or trouble swallowing. Doctors diagnose stomach cancer with a physical exam, blood and imaging tests, an endoscopy, and a biopsy. Because it is often found late, it can be hard to treat stomach cancer. Treatment options include surgery, chemotherapy, radiation or a combination. NIH: National Cancer Institute

KEGG : 36 Gastric cancer (GC) is one of the world's most common cancers. According to Lauren's histological classification gastric cancer is divided into two distinct histological groups - the intestinal and diffuse types. Several genetic changes have been identified in intestinal-type GC. The intestinal metaplasia is characterized by mutations in p53 gene, reduced expression of retinoic acid receptor beta (RAR-beta) and hTERT expression. Gastric adenomas furthermore display mutations in the APC gene, reduced p27 expression and cyclin E amplification. In addition, amplification and overexpression of c-ErbB2, reduced TGF-beta receptor type I (TGFBRI) expression and complete loss of p27 expression are commonly observed in more advanced GC. The main molecular changes observed in diffuse-type GCs include loss of E-cadherin function by mutations in CDH1and amplification of MET and FGFR2F.

UniProtKB/Swiss-Prot : 73 Gastric cancer: A malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease.

Wikipedia : 74 Stomach cancer, also known as gastric cancer, is a cancer that develops from the lining of the stomach.... more...

Sources

Related Diseases for Gastric Cancer

About this section

Diseases in the Gastric Cancer family:

Hereditary Gastric Cancer

Diseases related to Gastric Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1331)
# Related Disease Score Top Affiliating Genes
1 gastric adenocarcinoma 33.6 PIK3CA KRAS FGFR2 ERBB2
2 esophageal cancer 33.1 PIK3CA MIR93 MIR34A MIR21 MIR145 MIR143
3 colorectal cancer 33.1 PIK3CA MUTYH MIR93 MIR34A MIR27A MIR25
4 adenocarcinoma 33.1 PIK3CA KRAS FGFR2 ERBB2 APC
5 hepatocellular carcinoma 32.8 PIK3CA MIR93 MIR34A MIR27A MIR25 MIR222
6 breast cancer 32.7 PIK3CA MUTYH MIR34A MIR27A MIR222 MIR221
7 small intestine cancer 32.7 MUTYH KRAS ERBB2
8 lung cancer 32.7 PIK3CA MIR93 MIR34A MIR27A MIR25 MIR222
9 pancreatic cancer 32.6 PIK3CA MIR34A MIR25 MIR222 MIR221 MIR21
10 gastrointestinal system disease 32.6 MIR93 MIR34A MIR27A MIR25 MIR222 MIR221
11 bladder cancer 32.4 PIK3CA MIR34A MIR222 MIR221 MIR21 MIR145
12 lung cancer susceptibility 3 32.4 PIK3CA MIR21 MIR145 KRAS KLF6 FGFR2
13 adenoma 32.4 PIK3CA MUTYH KRAS APC
14 prostate cancer 32.4 PIK3CA MIR34A MIR27A MIR25 MIR222 MIR221
15 gastrointestinal system cancer 32.3 MIR93 MIR34A MIR27A MIR25 MIR222 MIR221
16 leukemia, chronic lymphocytic 32.2 MIR34A MIR27A MIR221 MIR21 MIR20A MIR145
17 rectum cancer 32.2 MUTYH MIR21 MIR20A MIR145 MIR143 KRAS
18 stomach disease 32.2 MIR93 MIR34A MIR27A MIR25 MIR222 MIR221
19 endometrial cancer 32.1 PIK3CA MUTYH MIR34A MIR145 KRAS FGFR2
20 ovarian cancer 32.1 PIK3CA MUTYH MIR34A MIR27A MIR25 MIR222
21 renal cell carcinoma, nonpapillary 32.1 PIK3CA MIR93 MIR34A MIR27A MIR221 MIR21
22 myeloma, multiple 32.0 PIK3CA MIR93 MIR27A MIR25 MIR21 MIR145
23 leukemia, acute myeloid 32.0 PIK3CA MIR34A MIR27A MIR222 MIR221 MIR21
24 body mass index quantitative trait locus 11 31.9 MIR93 MIR34A MIR27A MIR222 MIR221 MIR21
25 gastrointestinal stromal tumor 31.9 MIR143 KRAS ERBB2 APC
26 glioblastoma 31.9 PIK3CA MIR34A MIR25 MIR222 MIR221 MIR21
27 cholangiocarcinoma 31.9 PIK3CA MIR21 KRAS FGFR2 ERBB2 APC
28 lymphoma, non-hodgkin, familial 31.9 PIK3CA MIR34A MIR27A MIR222 MIR21 MIR20A
29 lynch syndrome 31.8 PIK3CA MUTYH KRAS APC
30 intestinal disease 31.8 MIR93 MIR34A MIR27A MIR25 MIR222 MIR221
31 pancreas disease 31.8 MIR93 MIR34A MIR27A MIR25 MIR221 MIR21
32 nasopharyngeal carcinoma 31.8 PIK3CA MIR93 MIR21 MIR143 FGFR2
33 dermatomyositis 31.8 MIR34A MIR222 MIR221 MIR21
34 li-fraumeni syndrome 31.7 PIK3CA MUTYH KRAS ERBB2
35 kidney cancer 31.7 PIK3CA MIR27A MIR21 MIR20A MIR106B
36 diffuse large b-cell lymphoma 31.7 MIR27A MIR222 MIR221 MIR21 MIR145 MIR143
37 melanoma 31.7 PIK3CA MIR34A MIR27A MIR222 MIR221 KRAS
38 intrahepatic cholangiocarcinoma 31.7 KRAS FGFR2 ERBB2 APC
39 colorectal adenoma 31.7 MUTYH MIR21 KRAS APC
40 glioma 31.7 PIK3CA MIR34A MIR25 MIR222 MIR221 MIR21
41 disease by infectious agent 31.7 MIR93 MIR34A MIR27A MIR221 MIR21
42 pancreatic ductal adenocarcinoma 31.6 MIR93 MIR222 MIR221 MIR21 MIR145 MIR143
43 cervical cancer 31.6 PIK3CA MIR93 MIR34A MIR21 MIR145 MIR143
44 neuroblastoma 31.6 PIK3CA MIR93 MIR34A MIR221 MIR21 ERBB2
45 in situ carcinoma 31.6 PIK3CA MIR143 ERBB2
46 arteries, anomalies of 31.5 MIR93 MIR34A MIR27A MIR25 MIR222 MIR221
47 connective tissue disease 31.5 MIR93 MIR34A MIR27A MIR222 MIR221 MIR21
48 respiratory system cancer 31.5 MIR93 MIR34A MIR27A MIR25 MIR222 MIR221
49 hematologic cancer 31.4 MIR93 MIR34A MIR27A MIR25 MIR222 MIR221
50 gallbladder cancer 31.3 PIK3CA MIR145 MIR143 KRAS ERBB2

Comorbidity relations with Gastric Cancer via Phenotypic Disease Network (PDN): (show all 11)


Active Peptic Ulcer Disease Acute Cystitis
Deficiency Anemia Gastric Fundus Cancer
Heart Disease Intestinal Obstruction
Iron Deficiency Anemia Neutropenia
Protein-Energy Malnutrition Pylorus Cancer
Stomach Carcinoma in Situ

Graphical network of the top 20 diseases related to Gastric Cancer:



Diseases related to Gastric Cancer
Sources

Symptoms & Phenotypes for Gastric Cancer

About this section

Human phenotypes related to Gastric Cancer:

31
# Description HPO Frequency HPO Source Accession
1 stomach cancer 31 HP:0012126
2 increased level of l-fucose in urine 31 HP:0410067

Clinical features from OMIM®:

613659 (Updated 05-Mar-2021)

UMLS symptoms related to Gastric Cancer:


nausea and vomiting, constipation, abdominal pain, diarrhea, dyspepsia, icterus, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Gastric Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.17 APC ERBB2 FGFR2 IRF1 KRAS MUTYH
Sources

Drugs & Therapeutics for Gastric Cancer

About this section

Drugs for Gastric Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 474)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
2
Pravastatin Approved Phase 4 81093-37-0 54687
3
Iron isomaltoside 1000 Approved, Investigational Phase 4 1370654-58-2
4
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
5
Nicotine Approved Phase 4 54-11-5 942 89594
6
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
7
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
8
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
9
Simethicone Approved Phase 4 8050-81-5
10
Morphine Approved, Investigational Phase 4 57-27-2 5288826
11
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
12
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
13
Clarithromycin Approved Phase 4 81103-11-9 84029
14
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
15
Metronidazole Approved Phase 4 443-48-1 4173
16
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
17
Pantoprazole Approved Phase 4 102625-70-7 4679
18
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
19
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
20
Ofloxacin Approved Phase 4 82419-36-1 4583
21
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
22
Iron Approved Phase 4 7439-89-6 23925 29936
23
Doxifluridine Investigational Phase 4 3094-09-5
24
Furazolidone Experimental, Vet_approved Phase 4 67-45-8 3435 5323714
25 Omega 3 Fatty Acid Phase 4
26 Purinergic P2Y Receptor Antagonists Phase 4
27 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
28 Hypolipidemic Agents Phase 4
29 Lipid Regulating Agents Phase 4
30 Anticholesteremic Agents Phase 4
31 Soybean oil, phospholipid emulsion Phase 4
32 Soy Bean Phase 4
33 Fat Emulsions, Intravenous Phase 4
34 Anticonvulsants Phase 4
35 Central Nervous System Stimulants Phase 4
36 Anti-Bacterial Agents Phase 4
37 Anti-Arrhythmia Agents Phase 4
38 glutamine Phase 4
39 Nicotinic Agonists Phase 4
40 Dopamine Agents Phase 4
41 Cytochrome P-450 Enzyme Inhibitors Phase 4
42 Dopamine Uptake Inhibitors Phase 4
43 European Mistletoe Phase 4
44 Viscum album peptide Phase 4
45 Cytochrome P-450 CYP3A Inhibitors Phase 4
46 N-monoacetylcystine Phase 4
47 Antioxidants Phase 4
48 Emollients Phase 4
49 calcium channel blockers Phase 4
50 Tocolytic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 1784)
# Name Status NCT ID Phase Drugs
1 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
2 Fast-track Surgery Recovery Program With Early Jejunostomy Nutrition Protocol Minimizes Time to Adjuvant Chemotherapy in Patients Undergoing Laparoscopic Gastrectomy for Gastric Cancer Unknown status NCT01766765 Phase 4
3 Phase IV Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Bevacizumab in Patients With Potentially Resectable Gastric Cancer With Liver Metastasis Unknown status NCT01962376 Phase 4 Oxaliplatin;Capecitabine;Oxaliplatin;Capecitabine;Bevacizumab
4 The CHOLEGAS Study: Multicentric Randomized, Double-Blinded, Controlled Trial of Gastrectomy Plus Prophylactic Cholecystectomy Versus Gastrectomy Only, in Adults Submitted to Gastric Cancer Surgery With Curative Intent. Unknown status NCT00757640 Phase 4
5 A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy Unknown status NCT02776527 Phase 4 Apatinib Mesylate Tablets
6 Efficacy of Perioperative Application of Omega-3 Polyunsaturated Fatty Acids on Postoperative Immunization in Gastric Cancer Patients - A Prospective, Randomized Clinical Trial Unknown status NCT01910948 Phase 4 omega-3 polyunsaturated fatty acids
7 Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer : A Multicenter, Randomized, Controlled and Prospective Trial Unknown status NCT02401971 Phase 4 Thalidomide;CPT-11
8 An Open Label, Single Group Assigned, Multicenter Study of Apatinib in Patients With Chemo-refractory Advanced or Metastatic Adenocarcinoma of Stomach or Gastroesophageal Junction Unknown status NCT02426034 Phase 4 Apatinib
9 Phase IV Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Herceptin in Patients With Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis Unknown status NCT02380131 Phase 4 Oxaliplatin plus Capecitabine;Herceptin
10 Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients With Advanced Colorectal or Gastric Cancer Treated With FOLFIRI Regimen Unknown status NCT01271582 Phase 4 Irinotecan, 5FU, leucovorin
11 Community-based Helicobacter Pylori Eradication With Two Sequential Antibiotic Regimens for the Residents and Migrants From a High-risk Area for Gastric Cancer Unknown status NCT00155389 Phase 4 Helicobacter pylori eradication
12 A Single Arm, Multi-center Study to Assess the Efficacy and Safety of Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in Non-squamous Non-small-cell Lung Cancer (NSCLC) Unknown status NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
13 Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
14 An Pilot Study to Assess the Efficacy of Intravenous Iron Isomaltoside 1000 (Monofer®) in the Management of Anaemia Associated With the Palliative Management of Oesophagogastric Adenocarcinoma Unknown status NCT01927328 Phase 4 Iron isomaltoside 1000
15 Randomized Clinical Trial of Omega-3 Fatty Acid-supplemented Parenteral Nutrition Versus Standard Parenteral Nutrition in Patients Undergoing Major Laparoscopic Abdominal Surgery Unknown status NCT01819961 Phase 4 MCT/LCT and fish oil;MCT/LCT
16 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
17 Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia: A Randomized Prospective Comparison of Snares and Injectate in the Resection of Large Sessile Colonic Polyps Completed NCT01471756 Phase 4
18 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
19 Sequential Versus Concomitant Therapy for Helicobacter Pylori Infection Completed NCT00656968 Phase 4 10-day sequential treatment;10-day concomitant therapy
20 Prospective Controlled Randomized Comparative Study About Quality of Life (QoL), Immunomodulation and Safety of Adjuvant Mistletoe Treatment in Patients With Gastric Carcinoma Receiving Chemotherapy After Operation Completed NCT01401075 Phase 4 mistletoe extract;doxifluridine
21 Effects of Ilaprazole 20mg on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone Endoscopic Submucosal Dissection(ESD) for Gastric Adenoma or Early Gastric Cancer. Completed NCT02638584 Phase 4 Ilaprazole;Rabeprazole
22 ONCOXIN® and Quality of Life in Cancer Patients in a Real World Setting Study Completed NCT03550482 Phase 4
23 Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection -a Prospective Randomized Controlled Study Completed NCT01914692 Phase 4 Somatostatin
24 The Effects of Intraoperative Dexmedetomidine Infusion on Postoperative Bowel Movement in Patients Undergoing Laparoscopic Gastrectomy Completed NCT02164448 Phase 4 the dexmedetomidine group;the control group
25 Comparison of the Analgesic Effect Between Intrathecal Morphine and IV-fentanyl Patient Controlled Analgesia (ITM-IVPCA) and Epidural PCA (PCEA) in Patients Undergoing Gastrectomy -Randomized Allocation Study- Completed NCT01234272 Phase 4 morphine;Ropivacaine
26 Comparison of the Effects of Continuous Epidural Analgesia and Continuous Intravenous Analgesia on Postoperative Bowel Movement in Patients Undergoing Laparoscopic Gastrectomy Completed NCT02458573 Phase 4
27 Effectiveness of Premedication With Simethicone or Simethicone Plus N-acetylcysteine vs. Placebo in Improving Visibility During Upper Endoscopy. Completed NCT01653171 Phase 4 Water (Placebo);Simethicone;N-acetylcysteine 500 mg;N-acetylcysteine 1000 mg
28 The Effect of Perioperative Intravenous Magnesium on Pain After Endoscopic Submucosal Dissection for Gastric Neoplasm: Prospective Randomized Double-blind Placebo Controlled Study Completed NCT02235246 Phase 4 Magnesium Sulfate;Normal saline
29 Title: The Impact of Immunostimulating Nutrition on Infectious Complications After Upper Gastrointestinal Surgery - A Prospective, Randomized, Clinical Trial. Completed NCT00558155 Phase 4 peptisorb;Stresson;Parenteral nutrition;Omegaven, Dipeptiven
30 Standard and Immunostimulating Enteral Nutrition in Patients After Extended Gastrointestinal Surgery - A Prospective, Randomized, Controlled Clinical Trial Completed NCT00576940 Phase 4 Reconvan;Peptisorb
31 Effect of H. Pylori Eradication on the Fate of H. Pylori-associated Gastric Polyp (Randomized Controlled Study) Completed NCT03065868 Phase 4 H. pylori eradication (Amoxaxillin, Lanston, Clarithromycin)
32 A Randomized, Controlled, Double-blind Trial of the Efficacy and Safety of CO2 vs Room Air Insufflation During ESD for Gastric Tumor Completed NCT01579071 Phase 4
33 Whether 18F-ALF-NOTA-PRGD2 PET/CT Scan Can Predict the Efficacy and Adverse Events of Apatinib in Patients With Malignancies. Completed NCT03384511 Phase 4 Apatinib
34 Comparison of Efficacy of Bismuth Potassium Citrate, Pectin Bismuth Capsules, and Pectin Bismuth Granules in the Treatment of Helicobacter Pylori (Hp) First-line Quadruple Regimen: a Multicenter, Randomized, Prospective, Comparative Clinical Trial Recruiting NCT04209933 Phase 4 Bismuth potassium citrate containing quadruple therapy;Colloidal pectin bismuth capsules containing quadruple therapy;Colloidal pectin bismuth particles A quadruple therapy;Colloidal pectin bismuth particles B quadruple therapy
35 Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality Recruiting NCT02047994 Phase 4 Triple therapy
36 A Clinical Study Investigating Adverse Drug Reactions and Their Biomarker Correlations in Stage IV Cancer Patients Following Individualized Therapy of Apatinib Recruiting NCT03475589 Phase 4 apatinib
37 The Use of Fibrin Glue Sealant (Tisseel®) as a Reinforcement of Esophagojejunal Anastomoses Will Decrease the Rate of Anastomotic Leak. Recruiting NCT03733639 Phase 4 Tisseel
38 PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-guided Irinotecan Dosing of gFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma Recruiting NCT02366819 Phase 4 Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
39 A Multicenter, Open-label Post Authorization Safety Study to Evaluate the Effect of LysaKare® Infusion on Serum Potassium Levels in GEP-NET Patients Eligible for Lutathera® Treatment Recruiting NCT04524442 Phase 4 arginine/lysine
40 The Effect of Postoperative Supplemental Parenteral Nutrition (SPN) in Gastric Cancer Patients Who Underwent Gastrectomy: A Multicenter Prospective Randomized Controlled Trial Not yet recruiting NCT04607057 Phase 4 Parenteral Nutrition Solutions
41 A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication Not yet recruiting NCT04660123 Phase 4 Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication
42 Indocyanine Green Lymphangiography as a Tool for Improving Lymphadenectomy in Gastric Cancer Not yet recruiting NCT04591028 Phase 4 Indocyanine green
43 Preoperative Intravenous Iron Therapy in Patients With Gastric Cancer Not yet recruiting NCT04168346 Phase 4 Ferric carboxymaltose;Placebos
44 An Open-label, Multicentre Phase IV Study of Trastuzumab in Combination With the Standard Therapy (as Per Routine Clinical Practice) as First-line Therapy in Patients With HER2 Positive Metastatic Gastric Cancer Terminated NCT01260194 Phase 4 trastuzumab [Herceptin]
45 Randomized Phase 3 Study of Xelox(Capecitabine Plus Oxaliplatin) Followed by Maintenance Capecitabine or Observation in Patients With Advanced Gastric Adenocarcinoma Unknown status NCT02289547 Phase 3 Capecitabine
46 Clinical Impact of Second-look Endoscopy After Endoscopic Submucosal Dissection of Gastric Neoplasm Unknown status NCT02005809 Phase 3
47 Prospective Phase III Trial Using Radical Gastrectomy With/Without HIPEC in Advanced Gastric Cancer Patients Including Adenocarcinoma of the Esophagogastric Junction Unknown status NCT02381847 Phase 3
48 Comparison of SEEOX and SOX Chemotherapeutic Regimens in Stage â…¢B/â…¢C Gastric Cancer Patients Unknown status NCT02338518 Phase 3 oxaliplatin;etoposide;pharmorubicin;S-1
49 A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer Unknown status NCT01198392 Phase 3 s-1 plus cisplatin;5-Fu plus cisplatin
50 A Prospective,Multicentral,Open-label,Randomized,Controlled,Phase III Clinical Trial to Compare S-1 Plus Oxaliplatin to S-1 as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Unknown status NCT01795027 Phase 3 S-1 plus oxaliplatin;S-1 single

Search NIH Clinical Center for Gastric Cancer

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Cisplatin
CISPLATIN PWDR
docetaxel
Floxuridine
Fluorouracil
Ifosfamide
irinotecan
Irinotecan hydrochloride
Methotrexate
Methotrexate Sodium

Cochrane evidence based reviews: stomach neoplasms

Sources

Genetic Tests for Gastric Cancer

About this section

Genetic tests related to Gastric Cancer:

# Genetic test Affiliating Genes
1 Stomach Cancer 29
Sources

Anatomical Context for Gastric Cancer

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Gastric Cancer:

19
Stomach

MalaCards organs/tissues related to Gastric Cancer:

40
Lymph Node, Liver, Bone, Colon, T Cells, Endothelial, Breast
Sources

Publications for Gastric Cancer

About this section

Articles related to Gastric Cancer:

(show top 50) (show all 39772)
# Title Authors PMID Year
1
Genetic alterations of the MYH gene in gastric cancer. 54 57 6
15273732 2004
2
Inactivating mutations of the caspase-10 gene in gastric cancer. 54 6 57
11973654 2002
3
Functionally inactivating point mutation in the tumor-suppressor IRF-1 gene identified in human gastric cancer. 57 6 54
9679752 1998
4
The APC gene, responsible for familial adenomatous polyposis, is mutated in human gastric cancer. 57 6
1317264 1992
5
Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. 61 54 57
18488030 2008
6
Analysis for microsatellite instability and mutations of the DNA mismatch repair gene hMLH1 in familial gastric cancer. 61 54 57
8938136 1996
7
miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. 61 54 47
18794849 2008
8
E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. 61 54 47
18328430 2008
9
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. 54 6
15608678 2005
10
Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. 54 57
11419427 2001
11
Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. 6 54
11325814 2001
12
Microsatellite instability and mutations of p53 and TGF-beta RII genes in gastric cancer. 54 57
8882883 1996
13
Clinicopathologic significance of the K-ras gene codon 12 point mutation in stomach cancer. An analysis of 140 cases. 61 6
7773929 1995
14
Family history and the risk of stomach and colorectal cancer. 57 61
1606546 1992
15
Complementary and alternative therapies for precancerous lesions of gastric cancer: A protocol for a Bayesian network meta analysis. 61 42
33466209 2021
16
The effect of trifluridine/tipiracil for patients with heavily pretreated metastatic gastric cancer: A protocol for systematic review and meta-analysis. 42 61
33466182 2021
17
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. 6
26266985 2015
18
PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. 6
26266975 2015
19
Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. 6
23100325 2013
20
Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome. 6
22683711 2012
21
Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. 6
22658544 2012
22
De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. 6
22729223 2012
23
De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. 6
22729224 2012
24
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. 6
22729222 2012
25
Keratinocytic epidermal nevi are associated with mosaic RAS mutations. 6
22499344 2012
26
MicroRNA-192 and -215 are upregulated in human gastric cancer in vivo and suppress ALCAM expression in vitro. 61 47
21119604 2011
27
A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. 47 61
21112772 2011
28
Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis. 6
21079152 2011
29
Inhibitory effects of miRNA-200c on chemotherapy-resistance and cell proliferation of gastric cancer SGC7901/DDP cells. 61 47
21114921 2010
30
Mosaicism for oncogenic G12D KRAS mutation associated with epidermal nevus, polycystic kidneys and rhabdomyosarcoma. 6
20805368 2010
31
Discordance for Schimmelpenning-Feuerstein-Mims syndrome in monochorionic twins supports the concept of a postzygotic mutation. 6
20949522 2010
32
Epigenetic regulation of miR-196b expression in gastric cancer. 61 47
20662076 2010
33
Hsa-mir-27a genetic variant contributes to gastric cancer susceptibility through affecting miR-27a and target gene expression. 61 47
20666778 2010
34
Short rare MUC6 minisatellites-5 alleles influence susceptibility to gastric carcinoma by regulating gene. 57
20506113 2010
35
MiR-150 promotes gastric cancer proliferation by negatively regulating the pro-apoptotic gene EGR2. 47 61
20067763 2010
36
Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells. 47 61
19503096 2009
37
Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. 61 47
19153141 2009
38
Down-regulation of miR-141 in gastric cancer and its involvement in cell growth. 61 47
19363643 2009
39
MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. 47 54
18789835 2009
40
miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. 47 61
18449891 2008
41
After Helicobacter pylori, genetic susceptibility to gastric carcinoma revisited. 57
17991176 2007
42
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. 6
17673550 2007
43
Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. 6
17332249 2007
44
Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. 57
16767218 2006
45
Genetic alterations of the KLF6 gene in gastric cancer. 57
15824733 2005
46
A full genome scan for gastric cancer. 57
15635081 2005
47
Gastric cancer originating from bone marrow-derived cells. 57
15567866 2004
48
Mutation of the PIK3CA gene in ovarian and breast cancer. 6
15520168 2004
49
Lung cancer: intragenic ERBB2 kinase mutations in tumours. 6
15457249 2004
50
High frequency of mutations of the PIK3CA gene in human cancers. 6
15016963 2004
Sources

Variations for Gastric Cancer

About this section

ClinVar genetic disease variations for Gastric Cancer:

6 (show top 50) (show all 94)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MUTYH NM_012222.2(MUTYH):c.1204C>T (p.Pro402Ser) SNV Pathogenic 5298 rs121908382 1:45797202-45797202 1:45331530-45331530
2 MUTYH NM_012222.2(MUTYH):c.1232A>G (p.Gln411Arg) SNV Pathogenic 5299 rs121908383 1:45797174-45797174 1:45331502-45331502
3 KLF6 NM_001300.6(KLF6):c.465C>A (p.Ser155Arg) SNV Pathogenic 7574 rs121909144 10:3824044-3824044 10:3781852-3781852
4 CASP10 NM_001230.5(CASP10):c.685-2146C>T SNV Pathogenic 7766 rs121909775 2:202070652-202070652 2:201205929-201205929
5 CASP10 NM_001230.5(CASP10):c.440T>C (p.Met147Thr) SNV Pathogenic 7768 rs121909776 2:202052521-202052521 2:201187798-201187798
6 KRAS NM_004985.5(KRAS):c.35G>A (p.Gly12Asp) SNV Pathogenic 12582 rs121913529 12:25398284-25398284 12:25245350-25245350
7 FGFR2 NM_000141.5(FGFR2):c.799T>C (p.Ser267Pro) SNV Pathogenic 13290 rs121918505 10:123279633-123279633 10:121520119-121520119
8 PIK3CA NM_006218.4(PIK3CA):c.3203dup (p.Asn1068fs) Duplication Pathogenic 13658 rs587776802 3:178952146-178952147 3:179234358-179234359
9 ERBB2 NM_004448.3(ERBB2):c.2326G>A (p.Gly776Ser) SNV Pathogenic 13879 rs28933369 17:37880997-37880997 17:39724744-39724744
10 IRF1 NM_002198.3(IRF1):c.22A>T (p.Met8Leu) SNV Pathogenic 14720 rs121912469 5:131825149-131825149 5:132489457-132489457
11 MUTYH NM_012222.2(MUTYH):c.725G>A (p.Arg242His) SNV Pathogenic 140877 rs140342925 1:45798117-45798117 1:45332445-45332445
12 FGFR2 NM_000141.5(FGFR2):c.1150G>A (p.Gly384Arg) SNV Pathogenic 478046 rs1554927408 10:123274768-123274768 10:121515254-121515254
13 FGFR2 NM_000141.5(FGFR2):c.755C>G (p.Ser252Trp) SNV Pathogenic 13272 rs79184941 10:123279677-123279677 10:121520163-121520163
14 FGFR2 NM_022970.3(FGFR2):c.314A>G (p.Tyr105Cys) SNV Pathogenic 449024 rs1434545235 10:123325014-123325014 10:121565500-121565500
15 MUTYH NM_001048174.2(MUTYH):c.1103-2A>G SNV Pathogenic 141282 rs587781628 1:45797230-45797230 1:45331558-45331558
16 MUTYH NM_001048174.2(MUTYH):c.305-1G>C SNV Pathogenic 234229 rs372267274 1:45798843-45798843 1:45333171-45333171
17 MUTYH NM_001128425.1(MUTYH):c.55C>T (p.Arg19Ter) SNV Pathogenic 127845 rs587780088 1:45800165-45800165 1:45334493-45334493
18 KRAS NM_004985.5(KRAS):c.34G>A (p.Gly12Ser) SNV Pathogenic 12584 rs121913530 12:25398285-25398285 12:25245351-25245351
19 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg) SNV Pathogenic 13652 rs121913279 3:178952085-178952085 3:179234297-179234297
20 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys) SNV Pathogenic 13655 rs104886003 3:178936091-178936091 3:179218303-179218303
21 FGFR2 NM_000141.5(FGFR2):c.1032G>A (p.Ala344=) SNV Pathogenic 13268 rs121918491 10:123276885-123276885 10:121517371-121517371
22 FGFR2 NM_000141.5(FGFR2):c.758C>G (p.Pro253Arg) SNV Pathogenic 13273 rs77543610 10:123279674-123279674 10:121520160-121520160
23 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr) SNV Pathogenic 39705 rs121913281 3:178952084-178952084 3:179234296-179234296
24 MUTYH NM_001048174.2(MUTYH):c.1103G>A (p.Gly368Asp) SNV Pathogenic 5294 rs36053993 1:45797228-45797228 1:45331556-45331556
25 MUTYH NM_001048174.2(MUTYH):c.1103G>A (p.Gly368Asp) SNV Pathogenic 5294 rs36053993 1:45797228-45797228 1:45331556-45331556
26 MUTYH NM_001048174.2(MUTYH):c.452A>G (p.Tyr151Cys) SNV Pathogenic 5293 rs34612342 1:45798475-45798475 1:45332803-45332803
27 FGFR2 NM_000141.5(FGFR2):c.1025G>A (p.Cys342Tyr) SNV Pathogenic 13263 rs121918487 10:123276892-123276892 10:121517378-121517378
28 FGFR2 NM_000141.5(FGFR2):c.1124A>G (p.Tyr375Cys) SNV Pathogenic 13277 rs121913478 10:123274794-123274794 10:121515280-121515280
29 APC NM_000038.6(APC):c.3867T>A (p.Cys1289Ter) SNV Pathogenic 545962 rs1554085355 5:112175158-112175158 5:112839461-112839461
30 APC NM_000038.6(APC):c.2805C>A (p.Tyr935Ter) SNV Pathogenic 810 rs137854575 5:112174096-112174096 5:112838399-112838399
31 APC NM_000038.6(APC):c.1660C>T (p.Arg554Ter) SNV Pathogenic 807 rs137854573 5:112164586-112164586 5:112828889-112828889
32 APC NM_000038.6(APC):c.933+1G>A SNV Pathogenic 233970 rs876660765 5:112151291-112151291 5:112815594-112815594
33 APC NM_000038.6(APC):c.847C>T (p.Arg283Ter) SNV Pathogenic 184999 rs786201856 5:112151204-112151204 5:112815507-112815507
34 APC NM_000038.6(APC):c.694C>T (p.Arg232Ter) SNV Pathogenic 42248 rs397515734 5:112128191-112128191 5:112792494-112792494
35 APC NM_000038.6(APC):c.646C>T (p.Arg216Ter) SNV Pathogenic 127312 rs62619935 5:112128143-112128143 5:112792446-112792446
36 APC NM_000038.6(APC):c.637C>T (p.Arg213Ter) SNV Pathogenic 140952 rs587781392 5:112116592-112116592 5:112780895-112780895
37 APC NM_000038.6(APC):c.70C>T (p.Arg24Ter) SNV Pathogenic 184702 rs145945630 5:112090657-112090657 5:112754960-112754960
38 APC NM_000038.6(APC):c.3199C>T (p.Gln1067Ter) SNV Pathogenic 803 rs137854571 5:112174490-112174490 5:112838793-112838793
39 APC NM_000038.6(APC):c.3359G>A (p.Gly1120Glu) SNV Pathogenic 802 rs28933379 5:112174650-112174650 5:112838953-112838953
40 APC NM_000038.6(APC):c.1312+3A>G SNV Likely pathogenic 217924 rs863225311 5:112155044-112155044 5:112819347-112819347
41 CDH1 NM_004360.5(CDH1):c.2494G>A (p.Val832Met) SNV Likely pathogenic 12246 rs35572355 16:68867247-68867247 16:68833344-68833344
42 TP53 NM_000546.6(TP53):c.847C>T (p.Arg283Cys) SNV Likely pathogenic 127824 rs149633775 17:7577091-7577091 17:7673773-7673773
43 CTNNB1 NM_001904.4(CTNNB1):c.109T>C (p.Ser37Pro) SNV Likely pathogenic 376234 rs121913228 3:41266112-41266112 3:41224621-41224621
44 FANCI NM_001113378.2(FANCI):c.1804C>T (p.Arg602Ter) SNV Likely pathogenic 929725 15:89828432-89828432 15:89285201-89285201
45 CTNNB1 NM_001904.4(CTNNB1):c.110C>A (p.Ser37Tyr) SNV Likely pathogenic 375894 rs121913403 3:41266113-41266113 3:41224622-41224622
46 FGFR2 NM_000141.5(FGFR2):c.1013G>A (p.Gly338Glu) SNV Likely pathogenic 374817 rs1057519044 10:123276904-123276904 10:121517390-121517390
47 CDH1 NM_004360.5(CDH1):c.1296C>G (p.Asn432Lys) SNV Likely pathogenic 186937 rs187862045 16:68847374-68847374 16:68813471-68813471
48 CTNNB1 NM_001904.4(CTNNB1):c.118A>G (p.Thr40Ala) SNV Likely pathogenic 376237 rs1057519836 3:41266121-41266121 3:41224630-41224630
49 NRAS NM_002524.5(NRAS):c.37G>A (p.Gly13Ser) SNV Likely pathogenic 376221 rs121434595 1:115258745-115258745 1:114716124-114716124
50 ERBB3 NM_001982.3(ERBB3):c.850G>A (p.Gly284Arg) SNV Likely pathogenic 376167 rs1057519803 12:56481922-56481922 12:56088138-56088138

UniProtKB/Swiss-Prot genetic disease variations for Gastric Cancer:

73 (show all 19)
# Symbol AA change Variation ID SNP ID
1 APC p.Gly817Cys VAR_005035
2 APC p.Ile880Thr VAR_005036 rs140029598
3 APC p.Asn942Asp VAR_005039
4 APC p.Gly1120Glu VAR_005042 rs28933379
5 APC p.Arg1171His VAR_005043 rs372481703
6 APC p.Phe1197Ser VAR_005045
7 APC p.Ile1259Thr VAR_005046
8 APC p.Gly1312Glu VAR_005050
9 APC p.Val1326Ala VAR_005052
10 CASP10 p.Met147Thr VAR_037428 rs121909776
11 IRF1 p.Met8Leu VAR_065134 rs121912469
12 IRF1 p.Trp11Arg VAR_065135 rs121912470
13 KRAS p.Gly12Val VAR_006840 rs121913529
14 KRAS p.Gly12Asp VAR_016026 rs121913529
15 KRAS p.Gly12Ser VAR_016028 rs121913530
16 KRAS p.Gly13Asp VAR_016029 rs112445441
17 KRAS p.Ala59Thr VAR_016030 rs121913528
18 KRAS p.Lys5Asn VAR_064849 rs104894361
19 MUTYH p.Pro402Ser VAR_026049 rs121908382

Cosmic variations for Gastric Cancer:

9 (show top 50) (show all 46209)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM94780361 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.1159G>A p.A387T 18:25226759-25226759 48
2 COSM131486960 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.1159G>A p.A387T 18:25226759-25226759 48
3 COSM140706619 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.499G>A p.A167T 18:25226759-25226759 48
4 COSM94777296 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.2285G>A p.R762H 18:25225633-25225633 48
5 COSM131495211 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.443G>A p.C148Y 18:25227475-25227475 48
6 COSM140704933 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.1625G>A p.R542H 18:25225633-25225633 48
7 COSM94795709 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.3434T>G p.V1145G 18:25224484-25224484 48
8 COSM94788727 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.443G>A p.C148Y 18:25227475-25227475 48
9 COSM140712668 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.-218G>A p.? 18:25227475-25227475 48
10 COSM131483683 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.2285G>A p.R762H 18:25225633-25225633 48
11 COSM131502188 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.3434T>G p.V1145G 18:25224484-25224484 48
12 COSM140717636 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.2774T>G p.V925G 18:25224484-25224484 48
13 COSM89892679 ZNF384 stomach,NS,carcinoma,adenocarcinoma c.1136G>A p.R379Q 12:6669044-6669044 48
14 COSM99686061 ZNF384 stomach,NS,carcinoma,adenocarcinoma c.1319G>A p.R440Q 12:6669044-6669044 48
15 COSM96892872 ZNF384 stomach,NS,carcinoma,adenocarcinoma c.1319G>A p.R440Q 12:6669044-6669044 48
16 COSM92495186 ZNF384 stomach,NS,carcinoma,adenocarcinoma c.971G>A p.R324Q 12:6669044-6669044 48
17 COSM90523509 ZNF341 stomach,NS,carcinoma,adenocarcinoma c.2512G>A p.A838T 20:33791485-33791485 48
18 COSM98293254 ZNF341 stomach,NS,carcinoma,adenocarcinoma c.2533G>A p.A845T 20:33791485-33791485 48
19 COSM84509305 ZNF276 stomach,NS,carcinoma,adenocarcinoma c.*677T>G p.? 16:89738923-89738923 48
20 COSM102042239 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.5456G>T p.R1819L 16:72794484-72794484 48
21 COSM149288723 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1081G>A p.G361R 16:72959065-72959065 48
22 COSM149261321 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1858C>T p.H620Y 16:72958288-72958288 48
23 COSM102020152 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.-23-7323C>T p.? 16:72958288-72958288 48
24 COSM87271088 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1858C>T p.H620Y 16:72958288-72958288 48
25 COSM87290698 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.795C>A p.D265E 16:72959351-72959351 48
26 COSM87291716 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.4553G>T p.G1518V 16:72798129-72798129 48
27 COSM149332052 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.5929G>C p.G1977R 16:72796753-72796753 48
28 COSM87280547 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1081G>A p.G361R 16:72959065-72959065 48
29 COSM102040971 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.-23-8386C>A p.? 16:72959351-72959351 48
30 COSM87291652 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.8198G>T p.R2733L 16:72794484-72794484 48
31 COSM87296752 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.5929G>C p.G1977R 16:72796753-72796753 48
32 COSM149318848 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.4553G>T p.G1518V 16:72798129-72798129 48
33 COSM149318790 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.8198G>T p.R2733L 16:72794484-72794484 48
34 COSM102042308 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1811G>T p.G604V 16:72798129-72798129 48
35 COSM149315912 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.795C>A p.D265E 16:72959351-72959351 48
36 COSM102030210 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.-23-8100G>A p.? 16:72959065-72959065 48
37 COSM102048038 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.3187G>C p.G1063R 16:72796753-72796753 48
38 COSM89893344 YES1 stomach,NS,carcinoma,adenocarcinoma c.350G>A p.R117K 18:751726-751726 48
39 COSM136835352 YES1 stomach,NS,carcinoma,adenocarcinoma c.365G>A p.R122K 18:751726-751726 48
40 COSM152021882 YES1 stomach,NS,carcinoma,adenocarcinoma c.350G>A p.R117K 18:751726-751726 48
41 COSM143039512 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 48
42 COSM145026456 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 48
43 COSM85235472 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 48
44 COSM128450026 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 48
45 COSM126971185 YAP1 stomach,NS,carcinoma,adenocarcinoma c.-179C>G p.? 11:102114178-102114178 48
46 COSM133271379 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 48
47 COSM127996054 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 48
48 COSM90945716 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 48
49 COSM97252932 XRCC2 stomach,NS,carcinoma,adenocarcinoma c.140A>G p.H47R 7:152649345-152649345 48
50 COSM101975785 XPO1 stomach,NS,carcinoma,adenocarcinoma c.479G>A p.S160N 2:61499824-61499824 48

Copy number variations for Gastric Cancer from CNVD:

7 (show top 50) (show all 694)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13401 1 1 2300000 Gain SLC35E2A Gastric cancer
2 13782 1 1 39600000 Gain LCK Gastric cancer
3 13783 1 1 39600000 Gain MDS2 Gastric cancer
4 13784 1 1 39600000 Gain PAX7 Gastric cancer
5 13785 1 1 39600000 Gain PRDM16 Gastric cancer
6 13786 1 1 39600000 Gain RPL22 Gastric cancer
7 13787 1 1 39600000 Gain SDHB Gastric cancer
8 13988 1 102200000 107200000 Loss AMY1A Gastric cancer
9 13989 1 102200000 107200000 Loss AMY2A Gastric cancer
10 19425 1 150222010 150233338 Amplification S100A10 Gastric cancer
11 22648 1 168031174 168088853 Amplification C1orf112 Gastric cancer
12 22794 1 168899937 168975165 Amplification PRRX1 Gastric cancer
13 24343 1 178867796 179122103 Amplification XPR1 Gastric cancer
14 25997 1 195319997 195382287 Amplification ASPM Gastric cancer
15 26293 1 198787930 198856485 Amplification KIF14 Gastric cancer
16 27965 1 216525252 216577948 Amplification RRP15 Gastric cancer
17 28583 1 223655827 223682407 Amplification LBR Gastric cancer
18 29302 1 2300000 5400000 Gain TP73 Gastric cancer
19 29303 1 2300000 5400000 Gain WRAP73 Gastric cancer
20 29725 1 234780594 234834437 Amplification HEATR1 Gastric cancer
21 30108 1 240078158 240119671 Amplification EXO1 Gastric cancer
22 30593 1 244770489 244796186 Amplification TFB2M Gastric cancer
23 37702 1 938709 939782 Copy number ISG15 Gastric cancer
24 37787 1 94700000 99700000 Loss DPYD Gastric cancer
25 38140 10 1 135006516 Loss Gastric cancer
26 40043 10 123336181 123337713 Amplification FGFR2 Gastric cancer
27 40401 10 127500000 130600000 Gain Gastric cancer
28 41839 10 24600000 135534747 Loss Gastric cancer
29 45622 10 73000000 81800000 Amplification PSAP Gastric cancer
30 48318 11 1 135006516 Gain Gastric cancer
31 49710 11 110400000 130800000 Gain Gastric cancer
32 49997 11 112500000 130800000 Gain Gastric cancer
33 53360 11 2800000 10700000 Gain CDKN1C Gastric cancer
34 53361 8 145646122 145661839 Gain CYHR1 Gastric cancer
35 53362 8 145669924 145672526 Gain FOXH1 Gastric cancer
36 53363 11 2800000 10700000 Gain KCNQ1 Gastric cancer
37 53364 11 2800000 10700000 Gain KCNQ1DN Gastric cancer
38 53365 8 145662545 145670307 Gain KIFC2 Gastric cancer
39 53366 11 2800000 10700000 Gain SLC22A18 Gastric cancer
40 53367 11 2800000 10700000 Gain SLC22A18AS Gastric cancer
41 54234 11 40200000 42900000 Amplification LRRC4C Gastric cancer
42 56156 11 57265297 57267459 Copy number SELENOH Gastric cancer
43 56517 11 59900000 61700000 Gain PGA5 Gastric cancer
44 58503 11 68100000 70400000 Amplification CCND1 Gastric cancer
45 58504 11 68100000 70400000 Amplification FGF3 Gastric cancer
46 58651 11 69161019 69306967 Amplification CCND1 Gastric cancer
47 58653 11 69161019 69306967 Amplification FGF19 Gastric cancer
48 58655 11 69161019 69306967 Amplification FGF4 Gastric cancer
49 58657 11 69161019 69306967 Amplification LTO1 Gastric cancer
50 59248 11 73719009 73787150 Amplification PGM2L1 Gastric cancer
Sources

Expression for Gastric Cancer

About this section
Search GEO for disease gene expression data for Gastric Cancer.
Sources

Pathways for Gastric Cancer

About this section

Pathways related to Gastric Cancer according to KEGG:

36
# Name Kegg Source Accession
1 Gastric cancer hsa05226

Pathways related to Gastric Cancer according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
PI3K-Akt signaling pathway 36
Show member pathways
 12.77 PIK3CA KRAS IRF1 FGFR2 ERBB2 APC
2
Endometrial cancer 36
Show member pathways
 12.7 PIK3CA KRAS FGFR2 ERBB2 APC
3
Pathways in cancer 36
12.67 PIK3CA KRAS FGFR2 ERBB2 APC
4
Gastric cancer 36
Show member pathways
 12.56 PIK3CA KRAS FGFR2 ERBB2 APC
5
VEGF Signaling 66
Show member pathways
 12.34 PIK3CA KRAS FGFR2 CASP10
6
Prolactin Signaling Pathway 1 36
Show member pathways
 12.32 PIK3CA KRAS IRF1 ERBB2
7
mTOR signaling pathway (KEGG) 36
Show member pathways
 12.27 PIK3CA KRAS FGFR2 ERBB2 APC
8
DNA Damage Response 1
Show member pathways
 12.2 MIR222 MIR221 MIR20A MIR106B
9
G-protein signaling RAC1 in cellular process 23
Show member pathways
 12.2 PIK3CA KRAS FGFR2 ERBB2 APC
10
Proteoglycans in cancer 36
12.09 PIK3CA MIR21 KRAS ERBB2
11
Apoptosis Pathway 70
Show member pathways
 12.08 PIK3CA KRAS FGFR2 ERBB2 CASP10
12
MicroRNAs in cancer 36
11.96 PIK3CA MIR34A MIR27A MIR25 MIR222 MIR221
13
Signaling pathways regulating pluripotency of stem cells 36
11.89 PIK3CA KRAS FGFR2 APC
14
Signaling by ERBB4 65
Show member pathways
 11.79 PIK3CA KRAS ERBB2
15
DNA Damage Response (only ATM dependent) 1
11.68 PIK3CA KRAS ERBB2 APC
16
VEGF Pathway (Tocris) 60
Show member pathways
 11.63 PIK3CA KRAS CASP10
17
Central carbon metabolism in cancer 36
11.3 PIK3CA KRAS FGFR2 ERBB2
18
miRNAs involved in DNA damage response 1
11.2 MIR93 MIR27A MIR25 MIR222 MIR221 MIR145
19
Extracellular vesicle-mediated signaling in recipient cells 1
11.02 KRAS ERBB2 APC
Sources

GO Terms for Gastric Cancer

About this section

Cellular components related to Gastric Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 MIR93 MIR27A MIR25 MIR222 MIR221 MIR21
2 extracellular vesicle GO:1903561 9.23 MIR93 MIR34A MIR27A MIR222 MIR221 MIR21

Biological processes related to Gastric Cancer according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 10.05 MIR93 MIR221 MIR21 IRF1 APC
2 actin cytoskeleton organization GO:0030036 9.93 PIK3CA MIR145 MIR143 KRAS
3 negative regulation of gene expression GO:0010629 9.93 MIR93 MIR34A MIR27A MIR21 MIR20A MIR106B
4 negative regulation of cell migration GO:0030336 9.92 MIR93 MIR34A MIR21 MIR145
5 negative regulation of inflammatory response GO:0050728 9.89 MIR222 MIR221 MIR20A MIR145
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.89 MIR27A MIR222 MIR221 MIR21 FGFR2
7 positive regulation of osteoblast differentiation GO:0045669 9.83 MIR27A MIR21 MIR20A
8 negative regulation of protein kinase B signaling GO:0051898 9.82 MIR34A MIR20A MIR145
9 positive regulation of epithelial to mesenchymal transition GO:0010718 9.8 MIR222 MIR221 MIR21
10 negative regulation of angiogenesis GO:0016525 9.8 MIR34A MIR222 MIR21 MIR145 MIR143 MIR106B
11 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.77 MIR93 MIR222 MIR221
12 negative regulation of sprouting angiogenesis GO:1903671 9.76 MIR34A MIR221 MIR20A
13 negative regulation of vascular endothelial growth factor production GO:1904046 9.73 MIR93 MIR34A MIR20A
14 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.73 MIR21 MIR20A MIR145 MIR106B
15 regulation of ERK1 and ERK2 cascade GO:0070372 9.72 MIR145 FGFR2 ERBB2
16 positive regulation of protein kinase B signaling GO:0051897 9.7 PIK3CA MIR222 MIR221 MIR21 MIR143 FGFR2
17 mesodermal cell differentiation GO:0048333 9.68 MIR145 FGFR2
18 positive regulation of axon regeneration GO:0048680 9.67 MIR222 MIR221
19 negative regulation by host of viral genome replication GO:0044828 9.67 MIR222 MIR221
20 regulation of microtubule-based process GO:0032886 9.67 ERBB2 APC
21 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.67 MIR221 MIR21 MIR20A MIR143
22 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.66 MIR222 MIR221
23 angiotensin-activated signaling pathway GO:0038166 9.66 MIR145 MIR143
24 negative regulation of regulatory T cell differentiation GO:0045590 9.65 MIR21 IRF1
25 negative regulation of cell adhesion molecule production GO:0060354 9.65 MIR222 MIR221 MIR20A
26 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.65 MIR27A MIR222 MIR221 MIR21 MIR20A
27 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.64 MIR27A MIR21
28 aorta smooth muscle tissue morphogenesis GO:0060414 9.63 MIR145 MIR143
29 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.61 MIR20A MIR143
30 regulation of phenotypic switching GO:1900239 9.61 MIR145 MIR143
31 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.58 MIR222 MIR221
32 negative regulation of interleukin-21 production GO:0032705 9.58 MIR222 MIR221 MIR21
33 positive regulation of Schwann cell migration GO:1900149 9.57 MIR222 MIR221
34 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 9.54 MIR222 MIR221
35 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.52 MIR222 MIR221
36 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.51 MIR145 MIR143
37 miRNA mediated inhibition of translation GO:0035278 9.5 MIR27A MIR222 MIR221 MIR21 MIR20A MIR145
38 gene silencing by miRNA GO:0035195 9.36 MIR93 MIR34A MIR27A MIR25 MIR222 MIR221

Molecular functions related to Gastric Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.56 MIR93 MIR34A MIR27A MIR21 MIR20A MIR145
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.36 MIR93 MIR34A MIR27A MIR25 MIR222 MIR221
Sources

Sources for Gastric Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....